5 Stocks Driving The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 15,060 as of Friday, May 10, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,550 issues advancing vs. 1,371 declining with 121 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is unchanged. Top gainers within the industry include Unilife Corporation ( UNIS), up 58.4%, St Jude Medical ( STJ), up 1.9%, Edwards Life ( EW), up 1.5%, Boston Scientific ( BSX), up 1.4% and HCA Holdings ( HCA), up 1.5%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 3.28, and Intuitive Surgical ( ISRG), down 2.41.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Hologic ( HOLX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Hologic is up $0.66 (3.19) to $21.16 on average volume Thus far, 1.8 million shares of Hologic exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $20.58-$21.24 after having opened the day at $20.60 as compared to the previous trading day's close of $20.51.

Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for the healthcare needs of women. Hologic has a market cap of $5.4 billion and is part of the health care sector. Shares are up 1.6% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Hologic Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Zimmer Holdings ( ZMH) is up $0.66 (0.84) to $78.94 on average volume Thus far, 478,421 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $77.79-$78.98 after having opened the day at $78.05 as compared to the previous trading day's close of $78.28.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $13.1 billion and is part of the health care sector. The company has a P/E ratio of 17.8, equal to the S&P 500 P/E ratio of 17.7. Shares are up 17.4% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Zimmer Holdings a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Zimmer Holdings Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Tenet Healthcare ( THC) is up $0.96 (2.01) to $48.64 on light volume Thus far, 448,854 shares of Tenet Healthcare exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $47.55-$48.80 after having opened the day at $47.76 as compared to the previous trading day's close of $47.68.

Tenet Healthcare Corporation, an investor-owned health care services company, owns and operates acute care hospitals, ambulatory surgery centers, diagnostic imaging centers, urgent care centers, and related health care facilities in the United States. Tenet Healthcare has a market cap of $5.0 billion and is part of the health care sector. The company has a P/E ratio of 137.3, above the S&P 500 P/E ratio of 17.7. Shares are up 46.8% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Tenet Healthcare a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Tenet Healthcare as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and poor profit margins. Get the full Tenet Healthcare Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Becton Dickinson ( BDX) is up $1.34 (1.37) to $99.09 on average volume Thus far, 621,616 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $98.16-$99.35 after having opened the day at $98.20 as compared to the previous trading day's close of $97.75.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $18.9 billion and is part of the health care sector. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7. Shares are up 24.8% year to date as of the close of trading on Thursday. Currently there are 3 analysts that rate Becton Dickinson a buy, 5 analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Agilent Technologies ( A) is up $0.53 (1.23) to $43.69 on average volume Thus far, 2.1 million shares of Agilent Technologies exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $43.04-$43.85 after having opened the day at $43.04 as compared to the previous trading day's close of $43.16.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $14.9 billion and is part of the health care sector. The company has a P/E ratio of 13.7, below the S&P 500 P/E ratio of 17.7. Shares are up 5.4% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Bring On the Bitcoin Futures Trading Insanity!

Bring On the Bitcoin Futures Trading Insanity!

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

These Stocks Have Changed Direction

These Stocks Have Changed Direction

How to Buy Great, Cheap Stocks When Indexes Are at All-Time Highs

How to Buy Great, Cheap Stocks When Indexes Are at All-Time Highs

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course